Maria Gabriella Matera
#150,122
Most Influential Person Now
Researcher
Maria Gabriella Matera's AcademicInfluence.com Rankings
Maria Gabriella Materacomputer-science Degrees
Computer Science
#7832
World Rank
#8240
Historical Rank
Machine Learning
#3037
World Rank
#3075
Historical Rank
Artificial Intelligence
#3331
World Rank
#3380
Historical Rank
Database
#4885
World Rank
#5074
Historical Rank
Download Badge
Computer Science
Maria Gabriella Matera's Degrees
- PhD Computer Science University of Milan
- Masters Computer Science University of Milan
Similar Degrees You Can Earn
Why Is Maria Gabriella Matera Influential?
(Suggest an Edit or Addition)Maria Gabriella Matera's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Pharmacology and Therapeutics of Bronchodilators (2012) (393)
- β2-agonist therapy in lung disease. (2013) (215)
- Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. (1998) (201)
- A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. (2016) (201)
- ACE2: The Major Cell Entry Receptor for SARS-CoV-2 (2020) (200)
- Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. (1995) (153)
- β2‐adrenoceptor agonists: current and future direction (2011) (148)
- The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. (2004) (148)
- Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter? (2020) (140)
- Optimizing drug delivery in COPD: The role of inhaler devices. (2017) (124)
- The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. (2016) (121)
- TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. (2010) (114)
- Ultra long-acting β2-agonists in development for asthma and chronic obstructive pulmonary disease (2005) (110)
- Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. (2016) (108)
- Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis (2018) (107)
- The functional impact of adding salmeterol and tiotropium in patients with stable COPD. (2004) (102)
- Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. (2005) (101)
- Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. (2015) (101)
- Clinical Pharmacokinetics of Salmeterol (2002) (93)
- Emerging inhaled bronchodilators: an update (2009) (93)
- Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. (2012) (92)
- Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. (2011) (92)
- Relationship between zinc and obesity. (1993) (90)
- Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. (2014) (85)
- Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. (1994) (85)
- Translational Study Searching for Synergy between Glycopyrronium and Indacaterol (2014) (81)
- Emerging anti-inflammatory strategies for COPD (2012) (81)
- Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis (2017) (77)
- Characterization of adenosine receptors involved in adenosine‐induced bronchoconstriction in allergic rabbits (1996) (75)
- 5-HT modifiers as a potential treatment of asthma. (2000) (74)
- Pharmacology and Therapeutics of Bronchodilators Revisited (2019) (74)
- Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone (2013) (72)
- Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells (2016) (70)
- Bronchodilators: current and future. (2014) (68)
- Adding a LAMA to ICS/LABA Therapy: A Meta‐analysis of Triple Combination Therapy in COPD (2019) (66)
- High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. (2012) (66)
- Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. (2005) (64)
- Adherence to COPD treatment: Myth and reality. (2017) (63)
- Inhaled β2-Adrenoceptor Agonists (2012) (62)
- Oxidation pathway and exacerbations in COPD: the role of NAC (2016) (59)
- Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. (2013) (58)
- Withdrawal of inhaled corticosteroids in COPD: A meta-analysis. (2017) (57)
- Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside. (2015) (57)
- Canakinumab for the treatment of chronic obstructive pulmonary disease. (2015) (56)
- The burden of obesity in asthma and COPD: Role of adiponectin. (2017) (55)
- Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation (2017) (55)
- Severe Asthma and Biological Therapy: When, Which, and for Whom (2019) (53)
- A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease. (1995) (53)
- LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment (2017) (53)
- Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis (2016) (51)
- Effects of serotonin on airways: recent developments (1995) (51)
- Pharmacological mechanisms leading to synergy in fixed‐dose dual bronchodilator therapy (2018) (50)
- Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi (2011) (50)
- Brain natriuretic peptide: Much more than a biomarker. (2016) (50)
- Pharmacologic characteristics of prulifloxacin. (2006) (49)
- Novel bronchodilators in asthma (2010) (48)
- The use of bronchodilators in the treatment of airway obstruction in elderly patients. (2006) (47)
- Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD. (2004) (47)
- ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD? (2007) (47)
- Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD. (2003) (45)
- Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi. (2011) (43)
- Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD. (1998) (42)
- Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine (2019) (42)
- Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. (2015) (42)
- Pharmacological modulation of beta-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. (2010) (41)
- Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease (2015) (41)
- TSLP Inhibitors for Asthma: Current Status and Future Prospects (2020) (40)
- A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease. (1996) (40)
- α1-Antitrypsin deficiency and chronic respiratory disorders (2020) (39)
- Interaction between corticosteroids and muscarinic antagonists in human airways. (2016) (39)
- Cardiovascular disease in patients with COPD. (2015) (39)
- PDE inhibitors currently in early clinical trials for the treatment of asthma (2014) (39)
- Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. (2017) (39)
- The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction. (2002) (39)
- Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness. (2016) (38)
- Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation. (2006) (38)
- The Challenges of Precision Medicine in COPD (2017) (38)
- An update on bronchodilators in Phase I and II clinical trials (2012) (37)
- The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease (2016) (36)
- Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease. (2002) (36)
- The influence of propofol, remifentanil and lidocaine on the tone of human bronchial smooth muscle. (2013) (36)
- Pharmacological characterization of adenosine receptors on isolated human bronchi. (2011) (36)
- Bronchial hyperresponsiveness and bacterial respiratory infections. (1991) (36)
- New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol (2013) (36)
- Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. (2019) (35)
- Treating systemic effects of COPD. (2007) (34)
- Inflammation – A New Therapeutic Target in Pneumonia (2005) (34)
- Protein prenylation contributes to the effects of LPS on EFS-induced responses in human isolated bronchi. (2011) (34)
- Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease (2013) (34)
- Doxofylline is not just another theophylline! (2017) (34)
- Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo (2020) (34)
- Molecular and cellular mechanisms underlying the therapeutic effects of budesonide in asthma. (2016) (33)
- Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease (2016) (33)
- A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD. (2003) (33)
- The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis (2017) (32)
- A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease. (1998) (31)
- The use of bronchodilators in stable chronic obstructive pulmonary disease. (1997) (31)
- Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. (2015) (31)
- Immunomodulatory impact of a synbiotic in Th1 and Th2 models of infection (2010) (31)
- Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update (2016) (31)
- Indacaterol for chronic obstructive pulmonary disease (COPD). (2010) (31)
- Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease. (1998) (30)
- Pharmacological treatments in asthma‐affected horses: A pair‐wise and network meta‐analysis (2017) (30)
- Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives (2015) (29)
- The effective treatment of COPD: Anticholinergics and what else? (2006) (29)
- Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD. (2006) (29)
- Formoterol Turbuhaler for as-needed therapy in patients with mild acute exacerbations of COPD. (2001) (28)
- Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease (2014) (28)
- Long acting β2 agonists and theophylline in stable chronic obstructive pulmonary disease (1999) (28)
- Theophylline in the inhibition of angiotensin-converting enzyme inhibitor-induced cough. (1993) (28)
- Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. (2006) (28)
- Tremor and β(2)-adrenergic agents: is it a real clinical problem? (2012) (28)
- The anti-proliferative effects of adiponectin on human lung adenocarcinoma A549 cells and oxidative stress involvement. (2019) (28)
- Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi. (2009) (28)
- Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways (2018) (27)
- Preclinical Evaluation of an Inhibitor of Cytosolic Phospholipase A2α for the Treatment of Asthma (2011) (27)
- Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi (2017) (27)
- Controversy surrounding the Sputnik V vaccine (2021) (27)
- Triple combinations in chronic obstructive pulmonary disease – is three better than two? (2014) (26)
- Tiotropium formulations and safety: a network meta-analysis (2017) (26)
- Should long-acting beta 2-agonists be considered an alternative first choice option for the treatment of stable COPD? (1999) (26)
- Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma (2017) (26)
- Effects of chronic treatment with the new ultra‐long‐acting β2‐adrenoceptor agonist indacaterol alone or in combination with the β1‐adrenoceptor blocker metoprolol on cardiac remodelling (2015) (26)
- Pharmacological treatment and current controversies in COPD (2019) (26)
- Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases (2017) (26)
- Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. (2019) (26)
- Treatment of COPD: moving beyond the lungs. (2012) (26)
- Phosphodiesterase Inhibitors for Chronic Obstructive Pulmonary Disease: What Does the Future Hold? (2014) (25)
- Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. (2019) (25)
- Muscarinic Receptor Antagonists. (2016) (25)
- Long-acting bronchodilators are the first-choice option for the treatment of stable COPD. (2004) (24)
- Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. (2015) (24)
- Delivering Antibacterials to the Lungs (2002) (24)
- Prospects for COPD treatment. (2020) (24)
- Ultra-Long-Acting β2-Adrenoceptor Agonists (2012) (24)
- Prenatal and postnatal antimony exposure in rats: effect on vasomotor reactivity development of pups. (1987) (24)
- Propofol protects against opioid-induced hyperresponsiveness of airway smooth muscle in a horse model of target-controlled infusion anaesthesia. (2015) (24)
- Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. (2012) (23)
- Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease (2018) (23)
- β-Adrenoceptor Modulation in Chronic Obstructive Pulmonary Disease: Present and Future Perspectives (2013) (23)
- Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how (2018) (23)
- Antiflammins suppress the A23187- and arachidonic acid-dependent chloride secretion in rabbit distal colonic mucosa. (1992) (23)
- Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. (2019) (23)
- Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review (2020) (23)
- Evaluation of adiponectin profile in Italian patients affected by obstructive sleep apnea syndrome. (2016) (23)
- Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease (2007) (22)
- Factors Influencing the Efficacy of COVID-19 Vaccines: A Quantitative Synthesis of Phase III Trials (2021) (22)
- Innervation of equine airways. (2002) (22)
- Comparative Effects of a Two-Week Treatment with Nebivolol and Nifedipine in Hypertensive Patients Suffering from COPD (2004) (22)
- Effect of the selective 5-HT2 antagonist ketanserin on adenosine-induced bronchoconstriction in asthmatic subjects. (1992) (22)
- Roflumilast in chronic obstructive pulmonary disease: evidence from large trials (2010) (22)
- Macrolide and occult infection in asthma (2004) (21)
- Review: Safety of long-acting β2 -agonists in the treatment of asthma (2007) (21)
- IL-17 in chronic obstructive pulmonary disease (2012) (21)
- &bgr;2‐Adrenoceptor signalling bias in asthma and COPD and the potential impact on the comorbidities associated with these diseases (2018) (21)
- Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD (2019) (21)
- Beta-blockers are safe in patients with chronic obstructive pulmonary disease, but only with caution. (2008) (21)
- Brain natriuretic peptide protects against hyperresponsiveness of human asthmatic airway smooth muscle via an epithelial cell-dependent mechanism. (2014) (20)
- Role of muscarinic antagonists in asthma therapy (2017) (20)
- Effects of neuraminidase on equine isolated bronchi. (2008) (20)
- Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. (2015) (20)
- Long-acting β2 agonists as potential option in the treatment of acute exacerbations of COPD (2003) (20)
- The cardiovascular risk of tiotropium: is it real? (2010) (20)
- Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics. (2016) (19)
- Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi (2017) (19)
- Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. (2013) (19)
- The future of bronchodilation: looking for new classes of bronchodilators (2019) (19)
- Oral bambuterol compared to inhaled salmeterol in patients with partially reversible chronic obstructive pulmonary disease (1999) (19)
- Guidance on nebulization during the current COVID-19 pandemic (2020) (19)
- Impact of doxofylline in COPD: A pairwise meta-analysis. (2018) (18)
- Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. (2019) (18)
- Pulmonary concentrations of dirithromycin and erythromycin during acute exacerbation of mild chronic obstructive pulmonary disease. (1997) (18)
- Emerging drugs for chronic obstructive pulmonary disease (2012) (17)
- Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. (2018) (17)
- Advances with glucocorticoids in the treatment of asthma: state of the art (2020) (17)
- Comparison of the Bronchodilating Effect of Salmeterol and Zafirlukast in Combination with That of Their Use as Single Treatments in Asthma and Chronic Obstructive Pulmonary Disease (2001) (16)
- Acute effects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD. (2002) (16)
- Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD. (1999) (16)
- Fixed-Dose Combination Inhalers. (2016) (16)
- Inhaled corticosteroids for chronic obstructive pulmonary disease (2013) (16)
- Muscarinic receptor subtypes in lung (1992) (16)
- How does race/ethnicity influence pharmacological response to asthma therapies? (2018) (15)
- Interrelationship between pharmacokinetics and pharmacodynamics in choosing the appropriate antibiotic and the dosage regimen for treating acute exacerbations of chronic bronchitis. (1998) (15)
- Long‐acting muscarinic antagonists and small airways in asthma: Which link? (2021) (15)
- QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease (2015) (15)
- Onset of action following formoterol Turbuhaler and salbutamol pMDI in reversible chronic airway obstruction. (2002) (15)
- Preexisting cardiorespiratory comorbidity does not preclude the success of multidisciplinary rehabilitation in post-COVID-19 patients (2021) (15)
- The latest on the role of LAMAs in asthma. (2020) (14)
- Effect of hyperbaric oxygen therapy in experimental subcutaneous and pulmonary infections due to Pseudomonas aeruginosa. (1999) (14)
- Influence of ethnicity on response to asthma drugs (2015) (14)
- Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab (2018) (14)
- Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent (2020) (14)
- An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? (2018) (14)
- Novel glucocorticoid receptor agonists in the treatment of asthma (2015) (14)
- A potential role of triple therapy for asthma patients (2019) (14)
- Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation (2014) (14)
- Bronchodilator therapy for chronic cough. (2017) (14)
- POINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? Yes. (2018) (13)
- N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. (2018) (13)
- Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease (2015) (13)
- The effect of doxofylline in asthma and COPD. (2020) (13)
- Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. (2005) (13)
- Use of Thiols in the Treatment of COVID-19: Current Evidence (2021) (13)
- Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. (2019) (13)
- N-acetylcysteine in COPD may be beneficial, but for whom? (2014) (13)
- Brain natriuretic peptide modulates calcium homeostasis and epidermal growth factor receptor gene signalling in asthmatic airways smooth muscle cells. (2015) (12)
- Pulmonary penetration of dirithromycin in patients suffering from acute exacerbation of chronic bronchitis. (1994) (12)
- Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells (2018) (12)
- Impact of rokitamycin, a new 16-membered macrolide, on serum theophylline. (1991) (12)
- Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease (2019) (12)
- Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients (2019) (12)
- Effects of chronic administration of β-blockers on airway responsiveness in a murine model of heart failure. (2014) (12)
- Alternative and/or integrative therapies for pneumonia under development (2004) (12)
- Novel approaches to the treatment of pneumonia. (2003) (12)
- Treatable Mechanisms in Asthma (2021) (11)
- Long-Acting β2-Agonists in the Treatment of Acute Exacerbations of COPD (2002) (11)
- The safety of dual bronchodilation on cardiovascular serious adverse events in COPD (2018) (11)
- Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. (2013) (11)
- Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. (2018) (11)
- The protective role of epithelium-derived nitric oxide in isolated bovine trachea. (2002) (11)
- Parenteral antibiotic therapy in the treatment of lower respiratory tract infections. Strategies to minimize the development of antibiotic resistance. (2000) (11)
- Implications of the Adiponectin System in Non-Small Cell Lung Cancer Patients: A Case-Control Study (2020) (10)
- Evaluation of lung tissue and hilar lymph node concentrations of azithromycin. (1994) (10)
- Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease (2015) (10)
- Ultra-LABAs for the treatment of asthma. (2019) (10)
- Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis (2019) (10)
- A review of the pharmacokinetics of M3 muscarinic receptor antagonists used for the treatment of asthma (2020) (10)
- Prospects for severe asthma treatment. (2020) (10)
- Bronchodilators in subjects with asthma-related comorbidities. (2019) (10)
- New treatments for COPD in the elderly. (2014) (10)
- Clinical effect of corticosteroids in asthma‐affected horses: A quantitative synthesis (2018) (10)
- Treatment options for moderate-to-very severe chronic obstructive pulmonary disease (2016) (10)
- Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol (2015) (10)
- Treatment of Chronic Obstructive Pulmonary Disease by Dual Bronchodilation with Coformulation of Indacaterol/Glycopyrronium (2014) (9)
- New anti-inflammatory approaches in COPD (2004) (9)
- Evidence for non-adrenergic non-cholinergic contractile responses in bovine and swine trachea. (1997) (9)
- Cardiac function and sympathetic activity in young diabetics. (1990) (9)
- Targeting IL‐5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab (2020) (9)
- Pharmacokinetics and Pharmacodynamics of Newer Oral Cephalosporins (1998) (9)
- Addition of an extra dose of salmeterol Diskus to conventional dose of salmeterol Diskus in patients with COPD. (2002) (9)
- To add, or not to add an inhaled corticosteroid in moderate COPD: that is the question. (2008) (9)
- Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease. (2018) (9)
- TNF- (cid:11) inhibitors in asthma and COPD: we must not throw the baby out with the bath water (2016) (8)
- Functional role of nitric oxide in guinea pig tracheal epithelium. (1995) (8)
- Varenicline for long term smoking cessation in patients with COPD. (2018) (8)
- New Avenues for Phosphodiesterase Inhibitors in Asthma (2021) (8)
- Combining long‐acting bronchodilators with different mechanisms of action: A pharmacological approach to optimize bronchodilation of equine airways (2018) (8)
- Sex differences in COPD management (2021) (8)
- An Acute Bronchodilator Test with Tiotropium or Salmeterol Does Not Allow a Subdivision of Patients according to Responses (2005) (8)
- Bronchodilator reversibility testing in post-COVID-19 patients undergoing pulmonary rehabilitation (2021) (8)
- Effects of in vitro 5-HT1 receptor activation in guinea pig trachea. (1996) (8)
- Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma (2018) (8)
- An update on the pharmacotherapeutic management of lower respiratory tract infections (2017) (8)
- Indacaterol, glycopyrronium, and mometasone: pharmacological interaction and anti-inflammatory profile in hyperresponsive airways. (2021) (8)
- Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses (2019) (8)
- Pharmacodynamic and pharmacokinetic assessment of fluticasone furoate + vilanterol for the treatment of asthma (2016) (7)
- The role of triple therapy in the management of COPD (2020) (7)
- Novelties in the field of antimicrobial compounds for the treatment of lower respiratory tract infections. (2003) (7)
- Bronchodilator response to formoterol Turbuhaler in patients with COPD under regular treatment with formoterol Turbuhaler. (2003) (7)
- Monoclonal antibodies in severe asthma: is it worth it? (2019) (7)
- Effects of some cephalosporins and teicoplanin on platelet aggregation. (1993) (7)
- Effect of lipopolysaccharide on the responsiveness of equine bronchial tissue. (2018) (7)
- Aclidinium bromide for the treatment of chronic obstructive pulmonary disease (2013) (7)
- Indacaterol for the treatment of chronic obstructive pulmonary disease (2015) (7)
- In vitro effect of reproterol upon pulmonary, cardiac, vascular and intestinal 3′, 5′‐monophosphate phosphodiesterase nucleoside (1982) (7)
- Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond (2014) (7)
- Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease (2018) (7)
- Rapid onset of bronchodilation with formoterol/beclomethasone Modulite and formoterol/budesonide Turbuhaler as compared to formoterol alone in patients with COPD. (2011) (7)
- Emerging muscarinic receptor antagonists for the treatment of asthma (2020) (7)
- Clinical pharmacokinetics of theophylline during co-treatment with ticarcillin plus clavulanic acid in patients suffering from acute exacerbation of chronic bronchitis. (1993) (6)
- Pharmacogenetic and pharmacogenomic considerations of asthma treatment (2017) (6)
- Combining Dual Bronchodilation and β-Blockade in Patients With an Overlap Between COPD and Cardiovascular Diseases. (2018) (6)
- Role of 5-hydroxytryptamine in mediating adenosine-induced airway contraction. (1995) (6)
- Aclidinium/formoterol fixed-dose combination for the treatment of chronic obstructive pulmonary disease. (2015) (6)
- Epithelial-smooth muscle cooperation is needed for brain natriuretic peptide-dependent bronchorelaxant activity. (2013) (6)
- Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis (2021) (6)
- Fluticasone furoate/vilanterol combination for the treatment of COPD and asthma. (2015) (6)
- Evidence of muscarinic receptor subtypes in airway smooth muscle of normal volunteers and of chronic obstructive pulmonary disease patients. (1989) (6)
- Drug interaction and chronic obstructive respiratory disorders (2020) (6)
- Quinidine-diltiazem: pharmacokinetic interaction in humans (1986) (6)
- Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease (2015) (6)
- Intrapulmonary penetration of antimicrobials and implications in the treatment of lower respiratory tract infections (2004) (6)
- Energy expenditure and impact of bronchodilators in COPD patients. (2010) (6)
- Pharmacological management of adult patients with acute respiratory distress syndrome (2020) (5)
- Cardiac function and sympathetic activity in young diabetics (1990) (5)
- A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD (2018) (5)
- Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children. (1993) (5)
- Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment (2021) (5)
- Effect of telenzepine, an M1-selective muscarinic receptor antagonist, in patients with nocturnal asthma. (1994) (5)
- The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians (2020) (5)
- Long-acting beta(2) agonists as potential option in the treatment of acute exacerbations of COPD. (2003) (5)
- Arformoterol tartrate in the treatment of COPD (2010) (5)
- Clinical synergism of LABA/LAMA combinations in COPD patients (2017) (5)
- Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy (2020) (5)
- RELATION BETWEEN ZINC AND OBESITY (1993) (5)
- Benralizumab for the treatment of asthma. (2017) (5)
- Protein tyrosin kinase and KCa++ cannel: two faces of the same coin in LABA/LAMA synergy (2017) (5)
- Ions and intracellular mechanisms involved in the effects of L-glutamate on arginine vasopressin release: in vitro researches on rat neurohypophysis. (1990) (5)
- Prenatal and postnatal metal exposure: effect on vasomotor reactivity development of pups: experimental research with antimony trichloride, thallium sulfate, and sodium metavanadate (1987) (5)
- Double or Triple Therapy in Chronic Obstructive Pulmonary Disease (2018) (4)
- Disputes over the production and dissemination of misinformation in the time of COVID-19 (2021) (4)
- New perspectives on the role of muscarinic antagonists in asthma therapy (2020) (4)
- Can FeNO be a biomarker in the post-COVID-19 patients monitoring? (2022) (4)
- Nitric oxide regulatory role in sensitized guinea pig trachea. (1997) (4)
- Medium-dose ICS-containing FDCs reduce all-cause mortality in COPD patients: an in-depth analysis of dual and triple therapies (2021) (4)
- Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents (2018) (4)
- Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma? (2016) (4)
- Association of β2-adrenergic agonists and tiotropium:is the combination justified? (2005) (4)
- Treatment of asthma during pregnancy: more solid evidence needed (2008) (4)
- A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study. (2019) (4)
- Is it time to look beyond bronchodilators and corticosteroids in treating COPD? (2021) (4)
- An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease (2021) (4)
- Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD) (2020) (4)
- An Obvious Paradigm: Choosing Bronchodilators and Inhaled Corticosteroids for Their Pharmacologic Characteristics. (2021) (4)
- Classes of drugs that target the cellular components of inflammation under clinical development for COPD (2021) (4)
- Step-up and step-down approaches in the treatment of asthma (2021) (4)
- Assessing the viability of long-acting β2-agonists in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective (2017) (4)
- Role of M1 muscarinic receptor subtypes in mediating airway smooth muscle contraction. (1993) (4)
- The future of inhalation therapy in chronic obstructive pulmonary disease (2022) (3)
- Triple Combination Inhalers in Chronic Obstructive Pulmonary Disease and Asthma (2020) (3)
- Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs (2021) (3)
- Long-acting β2 agonists in asthma and allergic rhinitis (2008) (3)
- Beyond Dual Bronchodilation – Triple Therapy, When and Why (2022) (3)
- Bronchodilators for Airway Disease (2020) (3)
- Interaction between tiotropium bromide and olodaterol in human bronchial smooth muscle (2017) (3)
- Role of nitric oxide on cholinergic component of bronchial tone in pig. (1996) (3)
- Inhibiting or blocking LIGHT, a TNF superfamily member, for treating airway remodeling (2011) (3)
- Calcium dependence of the evoked arginine vasopressin release by electrical stimulation and by L-glutamate. (1989) (3)
- Targeting IL-5 pathway against airway hyperresponsiveness: a challenge between benralizumab and mepolizumab (2020) (3)
- Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review (2020) (3)
- Corticosteroids in COPD (2003) (3)
- Excitatory amino acids and cardiovascular apparatus: experimental studies on conscious rats with L-glutamate, N-methyl-D-aspartate, kainate and quisqualate. (1990) (3)
- Dual bronchodilation for the treatment of COPD: From bench to bedside (2022) (3)
- Serum Digoxin Levels After Concomitant Ticarcillin and Clavulanic Acid Administration (1994) (3)
- Management of COPD patients during COVID: difficulties and experiences (2021) (3)
- Comments on “Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations” by D’Amato et al. (2021) (3)
- Pharmacokinetics and pharmacodynamics of newer oral cephalosporins: implications for treatment of community-acquired lower respiratory tract infections. (1998) (3)
- K+ channels and guinea-pig trachea: a possible functional modulation by GABAB receptors. (1994) (3)
- Physiological and pharmacological properties of an endogenous sodium pump inhibitor. (1997) (3)
- Unmet Needs and the Future of Asthma-Chronic Pulmonary Obstructive Disease Overlap. (2022) (2)
- Isolated airways in equine respiratory pharmacology: They never lie. (2019) (2)
- Long-lasting interaction study between RPL554 and glycopyrronium bromide on human isolated bronchi (2014) (2)
- Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease (2016) (2)
- Editorial overview: Respiratory: Pulmonary pharmacology - It is time for a breath of fresh air. (2018) (2)
- The Future of Bronchodilators in COPD and Asthma. (2021) (2)
- Interaction between RPL554 and glycopyrronium bromide in small human airways (2014) (2)
- Bioequivalence assessment of two different tablet formulations of diltiazem after single and repeated doses in healthy subjects. (1999) (2)
- Inhaled Corticosteroids in Adults with Non-cystic Fibrosis Bronchiectasis: From Bench to Bedside. A Narrative Review (2022) (2)
- Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. (2018) (2)
- Possible functional modulation by acetylcholine of nitric oxide on guinea pig isolated trachea. (1998) (2)
- Effects of the new ultra-long-acting β2-AR agonist indacaterol in chronic treatment alone or in combination with the β1-AR blocker metoprolol on cardiac remodelling (2015) (2)
- Drugs for the Treatment of Respiratory Diseases: Current and future management of pneumonia (2003) (2)
- Flomoxef, a new oxacephem antibiotic, does not cause hemostatic defects. (1993) (2)
- Interaction between tiotropium bromide and olodaterol in small human airways (2017) (2)
- Comparative studies of dual bronchodilation in COPD. (2021) (2)
- [Cardiac function (angiocardioscintigraphic evaluation) and plasma catecholamine levels in non-insulin-dependent diabetics]. (1991) (2)
- LABAs in asthmatic children: highlights and new inside. (2013) (2)
- Emerging anti-inflammatory strategies for chronic obstructive pulmonary disease (2012) (2)
- An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma (2022) (2)
- Evidence of muscarinic M1 receptors on human airways (1988) (1)
- Advances in the Pharmacological Management of Pediatric Acute Respiratory Distress Syndrome (2021) (1)
- Effect of exendin-4 on lung function of diabetic patients: a preliminary report (2017) (1)
- N-Acetylcysteine protects human bronchi via inhibiting neurokinin A (2017) (1)
- Contraction of bovine isolated bronchial airways: effects of epithelium removal. (1993) (1)
- Long-acting beta(2) agonists in asthma and allergic rhinitis. (2008) (1)
- β2-adrenoceptor modulation in COPD and its potential impact on cardiovascular comorbidities (2020) (1)
- Inhibition of platelet aggregation by some benzodiazepines (1989) (1)
- Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination (2020) (1)
- Long-acting muscarinic antagonists and small airways: which link? (2020) (1)
- Anxiety and depression in adolescents with asthma and in their parents. Is an increased basal cholinergic tone a possible further reason to explain the negative impact on asthma control? (2020) (1)
- Role of 5-HT2 receptors on adenosine-induced contraction of guinea-pig isolated trachea (1992) (1)
- Bronchodilator Response as a Possible Predictor of Lung Function Improvement After Pulmonary Rehabilitation in Post-COVID-19 Patients (2021) (1)
- Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today? (2022) (1)
- Blood Eosinophils in Chronic Obstructive Pulmonary Disease: Is There Enough Evidence? (2021) (1)
- Molecular aspects of asthma. (2022) (1)
- Research on heterocyclic compounds. XIV - Imidazothiazole and imidazobenzothiazole derivatives: synthesis and antiinflammatory activity. (1983) (1)
- Neuronorm is a potent and water soluble neurokinin A receptor antagonist. (1998) (1)
- Adding a LAMA to ICS/LABA therapy: a meta-analysis of triple therapy in COPD (2019) (1)
- Rebuttal From Drs Cazzola and Matera. (2018) (1)
- Role of 5-HT2 receptor subtypes in mediating adenosine-induced airway contraction. (1992) (1)
- The 5T approach in asthma: Triple Therapy Targeting Treatable Traits. (2022) (1)
- Lung blood flow must be considered when prescribing a long-acting β2-agonist/inhaled corticosteroid combination. (2012) (1)
- IND/GLY/MF: synergism in medium and small human hyperresponsive airways (2020) (1)
- [Heart function (angioscintigraphic evaluation) and sympathetic tone in insulin-dependent diabetes mellitus]. (1990) (1)
- Mechanisms leading to the bronchorelaxant synergy of ICS/LABA/LAMA combination (2019) (1)
- HDL-cholesterol/total cholesterol ratio increase produced in rats by intraperitoneal administration of various benzodiazepines in margarine-induced hyperlipidemia (1986) (1)
- Muscarinic M-1 receptors mediate the bronchial hyperresponsiveness during methacholine inhalation. (1989) (1)
- Ensifentrine. Dual phosphodiesterase PDE3/4 inhibitor, Treatment of COPD, Treatment of cystic fibrosis (2019) (1)
- Asthma and comorbidities: recent advances. (2022) (1)
- Teicoplanin with other drugs: possible pharmacological interactions. (1993) (1)
- Mucolytic and Antioxidant Properties of Carbocysteine as a Strategy in COVID-19 Therapy (2022) (1)
- Newer Cephalosporins are Only Marginal Advancements Over Existing Compounds (2002) (1)
- Efficacy of erdosteine, carbocysteine, and N-acetylcysteine in COPD: a comparative analysis (2019) (1)
- The cardiovascular effects of xanthines and selective PDE inhibitors: a risk–benefit analysis (2020) (1)
- Current long-acting muscarinic antagonists for the treatment of asthma (2021) (1)
- Effects Of Adenosine Receptor Agonist And Antagonists On Human Isolated Bronchi (2010) (0)
- Mechanisms leading to the bronchoprotective effects of N-Acetylcysteine in human bronchi stimulated by lipopolysaccharide (2018) (0)
- PGPM_A_231471 261..271 (2020) (0)
- Double bronchodilator therapy in COPD: a step forword Second edition (2014) (0)
- Indacaterol/mometasone furoate combination: synergism in human hyperresponsive airway smooth muscle (2020) (0)
- Arginine vasopressin and L-glutamate induced hypertension in freely moving rat (1990) (0)
- Nitric oxide and airways. (1998) (0)
- Characterization ofadenosine receptors involved inadenosine- induced bronchoconstrict ion inallergic rabbits (1996) (0)
- COPDCoRi, an algorithm for predicting the risk of coronaropathy in COPD patients (2014) (0)
- Effect of ICS/LABA combination in an ex vivo model of COPD exacerbation (2020) (0)
- Role of nitric oxide on acetylcholine release modulation in human and pig isolated bronchi (1995) (0)
- Interactions between inosine and adenosine: experimental researches. (1982) (0)
- Searching for synergistic interaction between aclidinium (ACL) and formoterol (FOR): From bench to bedside (2015) (0)
- Clinically important deterioration: a composite tool for managing patients with COPD. (2022) (0)
- Impact of glucagon-like peptide 1 receptor agonists on lung function of diabetic patients: a 52 weeks clinical trial (2018) (0)
- Pharmacological characterization of the protective effect of benralizumab against airway hyperresponsiveness in a human ex vivo model of severe asthma (2019) (0)
- Pharmacotherapy of LAMA/LABA inhaled therapy combinations for chronic obstructive pulmonary disease: a clinical overview (2022) (0)
- Contents Vol. 94, 2014 (2015) (0)
- The influence of acetylsalicylic acid, indomethacin, and flunoxaprofen on the fibrillation threshold in isolated guinea pig hearts (1991) (0)
- An Investigation Of The Role Of Histamine And Leukotrienes In Adenosine A1 Receptor Mediated Contraction Of Passively Sensitized Human Bronchial Preparations In Vitro (2011) (0)
- Long‐ And Ultra‐Long‐Acting β22‐Agonists (2012) (0)
- A long-term (2 years) efficacy and safety study of doxofylline in the treatment of asthma (2019) (0)
- Once- vs. twice-daily inhaled therapy in asthma: a network meta-analysis (2019) (0)
- Interaction between aclidinium bromide and formoterol fumarate in small human airways (2014) (0)
- COPD_A_345263 165..180 (2022) (0)
- Pharmacological profile of four new esters of isoxsuprine (1985) (0)
- Antioxidants and Protease Inhibitors (2003) (0)
- Mineral water and aspecific bronchial reactivity (1992) (0)
- The role of pharmacological treatment in the clinical deterioration of COPD: Can it be slowed down? (2022) (0)
- Long‑term management of patients with chronic obstructive pulmonary disease who undergo percutaneous coronary intervention still needs to be dramatically improved. (2018) (0)
- Editorial overview: Respiratory: Pulmonary pharmacology–The emergence of new treatments in pulmonary medicine is finally providing real therapeutic perspectives (2021) (0)
- Bronchiectasis and COVID-19 infection: a two-way street (2022) (0)
- Acutely clonidine treatment: catecholamines and serotonin in hypertensive patients (1985) (0)
- Effects of RO 5-4864 and PK 11195 on guinea pig trachea. (1995) (0)
- Mucolytics/antioxidants: When Are They Useful? (2023) (0)
- Effects of diazepam and pk 1195 and responses of some contractile agonists on guinea pig trachea (1992) (0)
- Bioavailability of timolol and aceclidine after ocular instillation in the rabbit. (1998) (0)
- Role of purinergic system in tracheobronchial reactivity of healthy and bronchopathic subjects. (1990) (0)
- Role of sympathoadrenal mechanisms and arginine vasopressin in hypertension induced by intracerebroventricular administration of N-methyl-D-aspartate in rats (1991) (0)
- The Challenges of Precision Medicine in COPD (2017) (0)
- Is there a rational for combining long-acting antimuscarinics and β2-agonists? (2014) (0)
- Brensocatib. Dipeptidyl peptidase 1 (DPP1) inhibitor, Treatment of non-cystic fibrosis bronchiectasis (2021) (0)
- Pharmacological characterization of the protective effect of mepolizumab against airway hyperresponsiveness in a human ex vivo model of severe asthma (2019) (0)
- Current and emerging treatment modalities for bacterial rhinosinusitis in adults: a comprehensive review (2022) (0)
- Contents, Vol. 60, 1993 (2004) (0)
- Responsiveness and sensitivity to cholinergic agonists and antagonists in bovine isolated bronchial muscles. (1990) (0)
- Systemic pharmacotherapy (2019) (0)
- Beclomethasone protects against human airway hyperresponsiveness induced by cow’s milk aspiration (2019) (0)
- AUTHOR PROOF COPY Not for publication (2015) (0)
- Is there a rationale for combining long-acting antimuscarinic agents and β2-agonists? (2012) (0)
- Effect of flomoxef on human platelet aggregation (2004) (0)
- Evidence for contractile NANC responses in bovine and swine trachea (1997) (0)
- Anxiety and asthma in inner-city black adolescents: What could be the underestimated, possible connection? (2018) (0)
- Pharmacological interaction between glycopyrronium bromide and indacaterol fumarate on the human airways tone (2016) (0)
- A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD (2022) (0)
- Reviews of "Qualitatively distinct modes of Sputnik V vaccine-neutralization escape by SARS-CoV-2 Spike variants" (2021) (0)
- The Role of Respiratory Drugs in Gastroesophageal Reflux (1999) (0)
- Subject Index, Vol. 60, 1993 (1993) (0)
- Effect of simvastatin on steroid-resistence in human epithelial cultured cells: A preliminary study (2015) (0)
- Pharmacological characterization of the mechanism of action leading to synergism between glycopyrronium bromide and indacaterol fumarate (2016) (0)
- Treatment of COPD: no longer nihilism, but there is still an urgent need for new therapies. (2012) (0)
- The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis [Corrigendum] (2018) (0)
- Ensifentrine: A First-in-class Bifunctional Drug for the Treatment of Chronic Obstructive Pulmonary Disease (2022) (0)
- Anti-inflammatory profile of N-acetylcysteine in human bronchi stimulated with lipopolysaccharide (2016) (0)
- Bronchodilator Response as a Possible Predictor of Lung Function Improvement After Pulmonary Rehabilitation in Post-COVID-19 Patients. (2021) (0)
- Related articles (2014) (0)
- Long-acting bronchodilators and synergistic interaction: a challenge across the currently available LABA/LAMA combinations (2018) (0)
- Effects of hyperbaric oxygen exposure on non-adrenergic non-cholinergic responses of rat trachea. (1997) (0)
- Chronic obstructive pulmonary disease b2-Agonists Antimuscarinic agents Methylxanthines Choice of bronchodilators Emerging bronchodilators (2014) (0)
- The effects of cholinergic antagonists on bovine isolated bronchial muscles with and without epithelium (1990) (0)
- Iconographies supplémentaires de l'article : Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients (2015) (0)
- New long—acting β2—agonist inhalers (2012) (0)
- Synergistic interaction between beclomethasone diproprionate and formoterol fumarate in an ex vivo model of bronchial asthma (2018) (0)
- Biologic therapies for chronic obstructive pulmonary disease (2022) (0)
- Prenatal and postnatal vanadium exposure in rats: effect on vasomotor reactivity development of pups. (1989) (0)
- Cardiac Effects ofFormoterol and Salmeterol inPatients Suffering From COPDWithPreexisting Cardiac Arrhythmias andHypoxemia (2015) (0)
- Aclidinium bromide inhalation powder for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema (2016) (0)
- Interaction between aclidinium bromide and formoterol fumarate; effects on human bronchial smooth muscle (2014) (0)
- [The therapeutic prospects of ischemic cardiopathy]. (1994) (0)
- Clinical characteristics, treatment patterns and adherence in patients with asthma on multiple inhaler triple therapy: a review of findings (2022) (0)
- RESPONSIVENESS AND SENSITIVITY TO CHOLINERGIC AGONISTS AND ANTAGONISTS IN BOVINE ISOLATED BRONCHIAL MUSCLE (1992) (0)
- Effects of MAPK inhibitors on H2O2-induced IL-8 production and cell death in primary cultures of human bronchial epithelial cells (2004) (0)
- Bronchodilators in bronchiectasis: there is light but it is still too dim (2022) (0)
- Bidimensional comparative analysis of LABA/LAMA FDCs in COPD (2019) (0)
- On the hypolipemic properties of bendaline. (1984) (0)
- Acknowledgement to Referees for Pharmacology 2014 (2015) (0)
- Anxiety/depression and impaired asthma control in adolescents. Is an increased basal cholinergic tone a possible link ? (2020) (0)
- Beclomethasone, formoterol and glycopyrronium: synergism of triple therapy on human airways (2019) (0)
- Pharmacological characterization of the anti-oxidant activity of N-acetylcysteine in anex vivomodel of COPD exacerbation (2016) (0)
- Influence Of Sensory Nerves And Neutral Endopeptidase On Human Isolated Bronchial Contraction Mediated By Adenosine A1 Receptor Activation (2011) (0)
- Evidence of muscarinic receptor in airway smooth muscle of normal volunteers and of subjects with chronic obstruction of the airways (1988) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Maria Gabriella Matera?
Maria Gabriella Matera is affiliated with the following schools:
